BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shallis RM, Bewersdorf JP, Boddu PC, Zeidan AM. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert Rev Anticancer Ther 2019;19:717-29. [PMID: 31422721 DOI: 10.1080/14737140.2019.1652095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Nie L, Zhang Y, You Y, Lin C, Li Q, Deng W, Ma J, Luo W, He H. The signature based on seven genomic instability-related genes could predict the prognosis of acute myeloid leukemia patients. Hematology 2022;27:840-8. [PMID: 35924822 DOI: 10.1080/16078454.2022.2107970] [Reference Citation Analysis]
2 Suchors C, Kim J. Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer. Cells 2022;11:2523. [PMID: 36010600 DOI: 10.3390/cells11162523] [Reference Citation Analysis]
3 Tesanovic S, Krenn PW, Aberger F. Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia—From bench to bedside. Front Cell Dev Biol 2022;10:944760. [DOI: 10.3389/fcell.2022.944760] [Reference Citation Analysis]
4 Lv G, Wang Y, Ji C, Shi C, Li Y. SPRY1 promotes cell proliferation and inhibits apoptosis by activating Hedgehog pathway in acute myeloid leukemia. Hematology 2022;27:1-10. [PMID: 34957932 DOI: 10.1080/16078454.2021.2010330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Rodrigues ACBDC, Costa RGA, Silva SLR, Dias IRSB, Dias RB, Bezerra DP. Cell signaling pathways as molecular targets to eliminate AML stem cells. Crit Rev Oncol Hematol 2021;160:103277. [PMID: 33716201 DOI: 10.1016/j.critrevonc.2021.103277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
6 Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, Hüttemann M, Taub JW, Ge Y. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther 2020;5:288. [PMID: 33335095 DOI: 10.1038/s41392-020-00361-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 20.5] [Reference Citation Analysis]
7 Bewersdorf JP, Carraway H, Prebet T. Emerging treatment options for patients with high-risk myelodysplastic syndrome. Ther Adv Hematol 2020;11:2040620720955006. [PMID: 33240476 DOI: 10.1177/2040620720955006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
8 Shallis RM, Boddu PC, Bewersdorf JP, Zeidan AM. The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Reviews 2020;40:100639. [DOI: 10.1016/j.blre.2019.100639] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
9 Ferrara F, Picardi A. Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation? Expert Rev Hematol 2020;13:99-108. [PMID: 31922453 DOI: 10.1080/17474086.2020.1715207] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis. Cancer Manag Res 2019;11:10777-90. [PMID: 31920387 DOI: 10.2147/CMAR.S212559] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]